These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 4206928)

  • 21. Trypanosoma cruzi glycoprotein of M(r) 56,000 characterization and assessment of its potential to protect against fatal parasite infections.
    Harth G; Mills AA; Lin T; Araujo FG
    Mol Microbiol; 1994 Jan; 11(2):261-71. PubMed ID: 8170388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of antigen preparations of the amastigote stage of Trypanosoma cruzi in the serology of Chagas' disease.
    Araujo FG; Guptill D
    Am J Trop Med Hyg; 1984 May; 33(3):362-71. PubMed ID: 6428245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of resistance and suppression of immunization against experimental Trypanosoma cruzi infection by Corynebacterium parvum.
    Kierszenbaum F
    Infect Immun; 1975 Nov; 12(5):1227-9. PubMed ID: 811568
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The immunology of experimental Chagas' disease. IV. Production of lesions in rabbits similar to those of chronic Chagas' disease in man.
    Teixeira AR; Teixeira ML; Santos-Buch CA
    Am J Pathol; 1975 Jul; 80(1):163-80. PubMed ID: 808136
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trypanosoma cruzi 80 kDa prolyl oligopeptidase (Tc80) as a novel immunogen for Chagas disease vaccine.
    Bivona AE; Sánchez Alberti A; Matos MN; Cerny N; Cardoso AC; Morales C; González G; Cazorla SI; Malchiodi EL
    PLoS Negl Trop Dis; 2018 Mar; 12(3):e0006384. PubMed ID: 29601585
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prime-boost immunization with cruzipain co-administered with MALP-2 triggers a protective immune response able to decrease parasite burden and tissue injury in an experimental Trypanosoma cruzi infection model.
    Cazorla SI; Frank FM; Becker PD; Corral RS; Guzmán CA; Malchiodi EL
    Vaccine; 2008 Apr; 26(16):1999-2009. PubMed ID: 18342408
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunology of Chagas' disease. III--Absorption of human chagasic sera with epimastigotes of different strains of Trypanosoma cruzi.
    Araujo FG; Nunes RM
    Rev Inst Med Trop Sao Paulo; 1978; 20(6):315-7. PubMed ID: 108797
    [No Abstract]   [Full Text] [Related]  

  • 28. A carbohydrate-containing antigen from Trypanosoma cruzi and its detection in the circulation of infected mice.
    Gottlieb M
    J Immunol; 1977 Aug; 119(2):465-70. PubMed ID: 69661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparative histopathological study of lesions produced by 2 strains of Trypanosoma cruzi].
    Andrade SG; Andrade ZA
    Hospital (Rio J); 1966 Nov; 70(5):1267-78. PubMed ID: 4969516
    [No Abstract]   [Full Text] [Related]  

  • 30. Parasite specific antibodies in three strains of mice after infection with Trypanosoma cruzi.
    Zweerink HJ; Anderson OF; Greenblatt HC; Murray PK
    J Parasitol; 1985 Feb; 71(1):43-9. PubMed ID: 3920376
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell surface antigens of Trypanosoma cruzi: use of monoclonal antibodies to identify and isolate an epimastigote specific glycoprotein.
    Snary D; Ferguson MA; Scott MT; Allen AK
    Mol Biochem Parasitol; 1981 Oct; 3(6):343-56. PubMed ID: 6795502
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Protective immunisation of mice using cell surface glycoprotein from Trypanosoma cruzi.
    Scott MT; Snary D
    Nature; 1979 Nov; 282(5734):73-4. PubMed ID: 116128
    [No Abstract]   [Full Text] [Related]  

  • 33. Protection against challenge of mice experimentally infected with Trypanosoma cruzi.
    Szarfman A; Schmuñis GA; Vattuone NH; Yanovsky JF; Cossio PM; Arana RM
    Tropenmed Parasitol; 1977 Sep; 28(3):333-41. PubMed ID: 410127
    [No Abstract]   [Full Text] [Related]  

  • 34. The protective effect of the epimastigote forms of the PF strain of Trypanosoma cruzi against a virulent homologous infection.
    Menezes H
    Tropenmed Parasitol; 1976 Dec; 27(4):418-21. PubMed ID: 827037
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Trypanosoma cruzi: lactate dehydrogenase isoenzymes and infections in mice.
    Mercado TI
    Exp Parasitol; 1976 Dec; 40(3):411-20. PubMed ID: 824154
    [No Abstract]   [Full Text] [Related]  

  • 36. Monoclonal antibodies mediating viable immunofluorescence and protection against Trypanosoma cruzi infection.
    Heath AW; Martins MS; Hudson L
    Trop Med Parasitol; 1990 Dec; 41(4):425-8. PubMed ID: 2127473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Coincidence of tissue antibody and cardiac pathology in mice infected with Trypanosoma cruzi.
    Lozykowski MG; McCormick TS; Rowland EC
    Trans R Soc Trop Med Hyg; 1991; 85(2):225-6. PubMed ID: 1909470
    [No Abstract]   [Full Text] [Related]  

  • 38. Trypanosoma cruzi: isolate dependence in the induction of lytic antibodies in the mouse and rabbit.
    Muller LA; Añasco N; González Cappa SM
    Exp Parasitol; 1986 Jun; 61(3):284-93. PubMed ID: 3086113
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trypanosoma cruzi: immune response in mice immunized with parasite antigens.
    Rottenberg ME; Cardoni RL; deTitto EH; Moreno M; Segura EL
    Exp Parasitol; 1988 Feb; 65(1):101-8. PubMed ID: 2892694
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 75Se-methionine labelled Trypanosoma cruzi blood trypomastigotes: opsonization by chronic infection serum facilitates killing in spleen and liver.
    Scott MT; Moyes L
    Clin Exp Immunol; 1982 Jun; 48(3):754-7. PubMed ID: 6811174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.